Rocket Pharmaceuticals Acquires Renovacor

Rocket Companies Acquires Mr. Cooper Group in $9.4 Billion All-Stock Transaction

March 31, 2025

Financial Services

Rocket Companies (NYSE: RKT) announced a definitive agreement to acquire Mr. Cooper Group Inc. in an all-stock deal valued at $9.4 billion in equity value (based on an 11.0x exchange ratio). The combined company is expected to service a combined mortgage portfolio of more than $2.1 trillion across nearly 10 million clients and generate substantial revenue and cost synergies.

Novo Nordisk to Acquire Cardior Pharmaceuticals for Up to €1.025 Billion

March 25, 2024

Biotechnology

Novo Nordisk agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion, consisting of an upfront payment plus additional milestone payments tied to development and commercial progress. The deal is expected to strengthen Novo Nordisk’s cardiovascular pipeline, centered on Cardior’s lead candidate CDR132L in phase 2 heart failure trials.

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.

Merck to Acquire Acceleron Pharma Inc for $11.5B

September 30, 2021

Biotechnology

Merck (through a subsidiary) entered into a definitive agreement to acquire Acceleron Pharma Inc for $180 per share in cash, for an approximate total equity value of $11.5 billion. The transaction will be completed via a tender offer followed by a merger, and is expected to close in the fourth quarter of 2021, subject to conditions including regulatory approvals and tender of at least a majority of outstanding shares.

Chardan Healthcare Acquisition 2 Corp. Completes Business Combination with Renovacor, Inc.

September 2, 2021

Biotechnology

Renovacor, an early‑stage biotechnology company developing AAV‑based gene therapies for BAG3‑associated cardiovascular and CNS diseases, closed a business combination with special purpose acquisition company Chardan Healthcare Acquisition 2 Corp. (CHAQ) and will begin trading on the New York Stock Exchange as Renovacor, Inc., with approximately $95.1 million of gross proceeds (including a $30.0 million PIPE) to fund clinical development into 2023. The transaction preserves Renovacor’s existing management team and provides public-market access and capital to advance its lead program, REN‑001, toward IND submission and a Phase I/II trial.

Redwire Acquires Roccor

October 29, 2020

Aerospace & Defense

Redwire has acquired Roccor, a Longmont, Colorado manufacturer of deployable booms, structures, antennas, thermal products and solar arrays for small satellites. Terms were not disclosed; the deal adds Roccor’s flight‑proven hardware to the Redwire platform (a company formed and backed by private equity firm AE Industrial Partners) to expand Redwire’s space infrastructure capabilities.